Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

Darren R Feldman,Sandy Srinivas,Patrick Nolan,Brian Addis Costello,Samuel Funt,Matthew I Milowsky,David I Quinn,George J Bosl,Sujata Patil,Hikmat Al-Ahmadie,Victor E Reuter,Maria Bromberg,Walter Michael Stadler,Robert J Motzer,Leonard Joseph Appleman,Tanya B Dorff,Dean F Bajorin,James Hu

doi:10.1200/jco.2018.36.15_suppl.4508

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

Darren R Feldman, Sandy Srinivas + Show 16 more

https://doi.org/10.1200/jco.2018.36.15_suppl.4508

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2018
Citations: 10

Affiliation: Memorial Sloan Kettering Cancer Center, Stanford University, Mayo Clinic, University of North Carolina Health Care, USC Norris Cancer Hospital, University of Southern California, University of Chicago, University of Pittsburgh

#Poor-risk Germ Cell Tumors #Germ Cell Tumors + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

4508Background: A prior single arm phase 2 trial of TIP in intermediate- and poor-risk GCT found superior rates of response, progression-free survival (PFS), and overall survival (OS) compared to h...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.